Spiro Rombotis, President and CEO of Cyclacel Pharmaceuticals, Inc., presides over the Closing bell.

About Cyclacel Pharmaceuticals, Inc. [CYCC]:

Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three Cyclacel drugs are in clinical development. Sapacitabine (CYC682), an orally-available cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly and cutaneous T-cell lymphoma (CTCL). Seliciclib (CYC202), an orally-available CDK (cyclin dependent kinase) inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. CYC116, an orally-available, Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. Several additional programs are at an earlier stage. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair(tm) Cream for radiation dermatitis, Numoisyn(tm) Liquid and Numoisyn(tm) Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in oncology, hematology and other therapeutic areas based on a portfolio of commercial products and a development pipeline of novel drug candidates.

Note: The Cyclacel logo and Cyclacel(r) are trademarks of Cyclacel Pharmaceuticals, Inc. Numoisyn(tm) and Xclair(tm) are trademarks of Sinclair Pharma plc.

For more information about Cyclacel Pharmaceuticals, Inc. [CYCC], please visit www.cyclacel.com www.cyclacel.com/.

Organizations interested in obtaining NASDAQ-listed company bell ringing ceremony photographs for press purposes, must first receive approval from the listed company before requesting photographs from NASDAQ. Please provide the company contact information from whom you received approval to Jolene Libretto at jolene.libretto@nasdaq.com. Kindly credit © 2008, The Nasdaq Stock Market, Inc. Reprinted with permission.

For all other photography inquiries, please contact NASDAQ’s photographer, Rob Tannenbaum at rob.tannenbaum@nasdaq.com.

© Copyright 2008, The NASDAQ Stock Market, Inc.
Reprinted with the permission of The Nasdaq Stock Market, Inc.

Copyright | Disclaimer | Trademarks | Privacy Statement | Contact Us | Help | Search